Iovance Biotherapeutics, Inc. (IOVA) 10-Year Financial Performance & Capital Metrics

IOVA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Show more

Revenue $164M +13699.0%
EBITDA -$352M +17.7%
Net Income -$372M +16.2%
EPS (Diluted) -1.28 +32.3%
Gross Margin 24.43% +103.0%
EBITDA Margin -214.34% +99.4%
Operating Margin -240.92% +99.4%
Net Margin -226.84% +99.4%
ROE -57.48% +29.8%
ROIC -49.47% +35.6%
Debt/Equity 0.08 -36.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 23.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM175.63%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.02%

EPS CAGR

10Y-

5Y-

3Y-

TTM19.46%

ROCE

10Y Avg-52.39%

5Y Avg-58.39%

3Y Avg-63.88%

Latest-54.22%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	1.19M	164.07M
Revenue Growth %	-	-	-	-	-	-	-	-	-	136.99%
Cost of Goods Sold+	999K	978K	952K	956K	8.12M	0	0	0	10.76M	124M
COGS % of Revenue	-	-	-	-	-	-	-	-	9.05%	0.76%
Gross Profit+	-999K	-978K	-952K	-956K	-8.12M	0	0	0	-9.57M	40.08M
Gross Margin %	-	-	-	-	-	-	-	-	-8.05%	0.24%
Gross Profit Growth %	0.89%	0.02%	0.03%	-0%	-7.5%	1%	-	-	-	5.19%
Operating Expenses+	27.86M	53.64M	92.88M	128.26M	206.87M	261.94M	342.7M	398.88M	450.99M	435.35M
OpEx % of Revenue	-	-	-	-	-	-	-	-	379.3%	2.65%
Selling, General & Admin	12.39M	17.2M	21.26M	28.43M	40.85M	60.21M	83.66M	104.1M	106.92M	153.02M
SG&A % of Revenue	-	-	-	-	-	-	-	-	89.92%	0.93%
Research & Development	15.47M	28.04M	71.61M	99.83M	166.02M	201.73M	259.04M	294.78M	344.08M	282.34M
R&D % of Revenue	-	-	-	-	-	-	-	-	289.38%	1.72%
Other Operating Expenses	0	9.5M	0	0	0	0	0	0	0	0
Operating Income+	-27.86M	-53.64M	-92.88M	-128.26M	-206.87M	-261.94M	-342.7M	-398.88M	-460.56M	-395.28M
Operating Margin %	-	-	-	-	-	-	-	-	-387.35%	-2.41%
Operating Income Growth %	-1.31%	-0.93%	-0.73%	-0.38%	-0.61%	-0.27%	-0.31%	-0.16%	-0.15%	0.14%
EBITDA+	-26.86M	-52.66M	-91.92M	-127.3M	-198.75M	-260.8M	-328.72M	-377.74M	-427.43M	-351.67M
EBITDA Margin %	-	-	-	-	-	-	-	-	-359.49%	-2.14%
EBITDA Growth %	-1.25%	-0.96%	-0.75%	-0.38%	-0.56%	-0.31%	-0.26%	-0.15%	-0.13%	0.18%
D&A (Non-Cash Add-back)	999K	978K	952K	956K	8.12M	1.14M	13.98M	21.14M	33.13M	43.61M
EBIT	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-261.94M	-342.7M	-398.88M	-460.56M	-395.28M
Net Interest Income+	0	0	0	0	9.32M	2.36M	451K	0	13.04M	20.27M
Interest Income	200K	745K	813K	0	9.32M	2.36M	451K	2.98M	13.04M	20.27M
Interest Expense	200K	0	0	0	0	0	0	2.98M	0	0
Other Income/Expense	200K	745K	813K	4.68M	9.32M	2.36M	451K	2.98M	13.04M	20.27M
Pretax Income+	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-259.58M	-342.25M	-395.89M	-447.52M	-375M
Pretax Margin %	-	-	-	-	-	-	-	-	-376.38%	-2.29%
Income Tax+	0	0	0	0	0	0	0	0	-3.48M	-2.83M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.99%	0.99%
Net Income+	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-259.58M	-342.25M	-395.89M	-444.04M	-372.18M
Net Margin %	-	-	-	-	-	-	-	-	-373.45%	-2.27%
Net Income Growth %	-1.3%	-0.91%	-0.74%	-0.34%	-0.6%	-0.31%	-0.32%	-0.16%	-0.12%	0.16%
Net Income (Continuing)	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-259.58M	-342.25M	-395.89M	-444.04M	-372.18M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.62	-0.96	-1.41	-1.27	-1.50	-1.88	-2.23	-2.49	-1.89	-1.28
EPS Growth %	-0.29%	-0.55%	-0.47%	0.1%	-0.18%	-0.25%	-0.19%	-0.12%	0.24%	0.32%
EPS (Basic)	-0.62	-0.96	-1.41	-1.27	-1.50	-1.88	-2.23	-2.49	-1.89	-1.28
Diluted Shares Outstanding	44.41M	55.27M	65.24M	97.28M	124.34M	138.3M	153.41M	159.26M	235.13M	289.88M
Basic Shares Outstanding	44.41M	55.27M	65.24M	97.28M	124.34M	138.3M	153.41M	159.26M	235.13M	289.88M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	103.98M	169.51M	149.29M	475.37M	316.49M	636.1M	507.96M	479.12M	307.85M	457.02M
Cash & Short-Term Investments	103.7M	166.47M	145.37M	468.52M	307.08M	629.44M	504.41M	471.85M	279.87M	323.78M
Cash Only	103.7M	166.47M	145.37M	82.15M	13.97M	67.33M	78.23M	231.73M	114.89M	115.69M
Short-Term Investments	0	0	0	386.37M	293.11M	562.11M	426.18M	240.11M	164.98M	208.09M
Accounts Receivable	0	0	0	0	0	0	0	0	151K	69.34M
Days Sales Outstanding	-	-	-	-	-	-	-	-	46.35	154.26
Inventory	0	0	0	0	0	0	0	0	10.37M	51.52M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	352	151.66
Other Current Assets	0	3.04M	3.92M	6.85M	0	0	0	7.27M	17.46M	12.38M
Total Non-Current Assets+	1.68M	2.37M	6.08M	5.45M	28.16M	132.36M	269.38M	184.87M	472.5M	453.41M
Property, Plant & Equipment	1.68M	2.37M	2.45M	2.68M	19.23M	113.92M	169.92M	178.25M	176.54M	164.28M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	0.01x	1.00x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	229.26M	282.4M
Long-Term Investments	0	0	0	0	0	0	91.59M	0	66.43M	0
Other Non-Current Assets	0	0	3.63M	2.76M	8.93M	18.44M	7.87M	6.62M	270K	6.73M
Total Assets+	105.65M	171.89M	155.37M	480.82M	344.65M	768.46M	777.33M	663.98M	780.35M	910.43M
Asset Turnover	-	-	-	-	-	-	-	-	0.00x	0.18x
Asset Growth %	1.27%	0.63%	-0.1%	2.09%	-0.28%	1.23%	0.01%	-0.15%	0.18%	0.17%
Total Current Liabilities+	1.63M	4.97M	9.89M	14.4M	39.08M	54.87M	89.2M	91.48M	110.31M	122.34M
Accounts Payable	958K	863K	1.23M	2.74M	15.57M	13.51M	27.38M	26.6M	33.12M	27.51M
Days Payables Outstanding	350.02	322.08	472.35	1.05K	699.49	-	-	-	1.12K	80.98
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	24K	2.52M	5.75M	7.55M	0	0	0	0	34.59M	50.03M
Current Ratio	63.79x	34.12x	15.09x	33.02x	8.10x	11.59x	5.69x	5.24x	2.79x	3.74x
Quick Ratio	63.79x	34.12x	15.09x	33.02x	8.10x	11.59x	5.69x	5.24x	2.70x	3.31x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-725.76	224.94
Total Non-Current Liabilities+	0	0	297K	230K	6.6M	57.09M	66.47M	72.86M	85.43M	77.68M
Long-Term Debt	0	0	0	0	0	0	1M	1M	1M	1M
Capital Lease Obligations	0	0	0	0	4.25M	45.38M	65.47M	71.86M	67.08M	44.37M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	17.35M	32.31M
Other Non-Current Liabilities	0	0	297K	230K	2.35M	11.71M	0	0	0	0
Total Liabilities	1.63M	4.97M	9.89M	14.63M	45.68M	111.96M	155.67M	164.34M	195.74M	200.02M
Total Debt+	0	0	0	0	11.5M	51.66M	71.53M	85.45M	75.86M	58.26M
Net Debt	-103.7M	-166.47M	-145.37M	-82.15M	-2.47M	-15.67M	-6.7M	-146.28M	-39.03M	-57.43M
Debt / Equity	-	-	-	-	0.04x	0.08x	0.12x	0.17x	0.13x	0.08x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-139.30x	-	-	-	-	-	-	-133.63x	-	-
Total Equity+	104.02M	166.92M	145.48M	466.19M	298.97M	656.5M	621.66M	499.64M	584.61M	710.4M
Equity Growth %	1.32%	0.6%	-0.13%	2.2%	-0.36%	1.2%	-0.05%	-0.2%	0.17%	0.22%
Book Value per Share	2.34	3.02	2.23	4.79	2.40	4.75	4.05	3.14	2.49	2.45
Total Shareholders' Equity	104.02M	166.92M	145.48M	466.19M	298.97M	656.5M	621.66M	499.64M	584.61M	710.4M
Common Stock	2K	3K	3K	5K	5K	6K	7K	8K	11K	13K
Retained Earnings	-104.22M	-157.12M	-249.18M	-372.76M	-570.61M	-830.19M	-1.17B	-1.57B	-2.01B	-2.38B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	48K	29K	0	-42K	220K	19K	-601K	-902K	2.53M	-1.05M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.38M	-32.67M	-78.71M	-101.25M	-158.89M	-205.13M	-227.94M	-292.76M	-361.82M	-352.98M
Operating CF Margin %	-	-	-	-	-	-	-	-	-304.31%	-2.15%
Operating CF Growth %	-1.13%	-0.78%	-1.41%	-0.29%	-0.57%	-0.29%	-0.11%	-0.28%	-0.24%	0.02%
Net Income	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-259.58M	-342.25M	-395.89M	-444.04M	-372.18M
Depreciation & Amortization	999K	978K	952K	956K	8.12M	1.14M	13.98M	21.14M	33.13M	43.61M
Stock-Based Compensation	8.52M	18.9M	11.97M	20.03M	24.28M	40.89M	69.77M	84.02M	62.63M	109.63M
Deferred Taxes	0	0	0	0	0	1.86M	0	0	-3.48M	-2.83M
Other Non-Cash Items	8.52M	-74K	19K	-1.32M	8.97M	7.57M	6.01M	871K	-3.54M	-8.65M
Working Capital Changes	-243K	418K	416K	2.67M	-2.7M	2.98M	24.55M	-2.89M	-6.52M	-122.56M
Change in Receivables	0	0	0	0	0	0	0	0	-149K	-69.19M
Change in Inventory	0	0	0	0	0	0	0	0	-10.12M	-39.92M
Change in Payables	-32K	-250K	369K	1.51M	0	-2.96M	6.98M	5.88M	4.83M	-7.84M
Cash from Investing+	-91.15M	8.89M	58.68M	-386.28M	90.03M	-317.85M	132K	256.45M	-155.24M	-96.41M
Capital Expenditures	-1.14M	-1.52M	-1.03M	-1.2M	-6.92M	-46.79M	-37.57M	-20.43M	-22.29M	-11.07M
CapEx % of Revenue	-	-	-	-	-	-	-	-	18.75%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-19.95M	10.41M	59.7M	-385.08M	96.94M	-271.06M	37.71M	276.88M	0	0
Cash from Financing+	78.27M	96.9M	58.69M	424.31M	6.13M	576.42M	239.27M	190.15M	462.96M	390.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-49.45M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-58.35M	50.67M	5.03M	-373.33M	6.44M	9.38M	35.11M	648K	-322K	-6.64M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.52M	-34.19M	-79.74M	-102.45M	-165.81M	-251.93M	-265.51M	-313.18M	-384.11M	-364.05M
FCF Margin %	-	-	-	-	-	-	-	-	-323.05%	-2.22%
FCF Growth %	-0.91%	-0.75%	-1.33%	-0.28%	-0.62%	-0.52%	-0.05%	-0.18%	-0.23%	0.05%
FCF per Share	-0.44	-0.62	-1.22	-1.05	-1.33	-1.82	-1.73	-1.97	-1.63	-1.26
FCF Conversion (FCF/Net Income)	0.66x	0.62x	0.85x	0.82x	0.80x	0.79x	0.67x	0.74x	0.81x	0.95x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-37.16%	-39.04%	-58.94%	-40.41%	-51.64%	-54.34%	-53.55%	-70.61%	-81.91%	-57.48%
Return on Invested Capital (ROIC)	-16138.87%	-10435.6%	-25056.74%	-50.08%	-45.6%	-41.92%	-40.93%	-61.79%	-76.85%	-49.47%
Gross Margin	-	-	-	-	-	-	-	-	-804.54%	24.43%
Net Margin	-	-	-	-	-	-	-	-	-37345.42%	-226.84%
Debt / Equity	-	-	-	-	0.04x	0.08x	0.12x	0.17x	0.13x	0.08x
Interest Coverage	-139.30x	-	-	-	-	-	-	-133.63x	-	-
FCF Conversion	0.66x	0.62x	0.85x	0.82x	0.80x	0.79x	0.67x	0.74x	0.81x	0.95x
Revenue Growth	-	-	-	-	-	-	-	-	-	13698.99%

Revenue by Geography

	2023	2024
UNITED STATES	-	161.04M
UNITED STATES Growth	-	-
Non-US	1.2M	3.03M
Non-US Growth	-	152.25%

Frequently Asked Questions

Growth & Financials

Iovance Biotherapeutics, Inc. (IOVA) reported $250.4M in revenue for fiscal year 2024.

Iovance Biotherapeutics, Inc. (IOVA) grew revenue by 13699.0% over the past year. This is strong growth.

Iovance Biotherapeutics, Inc. (IOVA) reported a net loss of $397.6M for fiscal year 2024.

Dividend & Returns

Iovance Biotherapeutics, Inc. (IOVA) has a return on equity (ROE) of -57.5%. Negative ROE indicates the company is unprofitable.

Iovance Biotherapeutics, Inc. (IOVA) had negative free cash flow of $351.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Iovance Biotherapeutics, Inc. (IOVA) 10-Year Financial Performance & Capital Metrics

IOVA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $164M +13699.0%
EBITDA -$352M +17.7%
Net Income -$372M +16.2%
EPS (Diluted) -1.28 +32.3%
Gross Margin 24.43% +103.0%
EBITDA Margin -214.34% +99.4%
Operating Margin -240.92% +99.4%
Net Margin -226.84% +99.4%
ROE -57.48% +29.8%
ROIC -49.47% +35.6%
Debt/Equity 0.08 -36.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 23.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM175.63%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.02%

EPS CAGR

10Y-

5Y-

3Y-

TTM19.46%

ROCE

10Y Avg-52.39%

5Y Avg-58.39%

3Y Avg-63.88%

Latest-54.22%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	1.19M	164.07M
Revenue Growth %	-	-	-	-	-	-	-	-	-	136.99%
Cost of Goods Sold+	999K	978K	952K	956K	8.12M	0	0	0	10.76M	124M
COGS % of Revenue	-	-	-	-	-	-	-	-	9.05%	0.76%
Gross Profit+	-999K	-978K	-952K	-956K	-8.12M	0	0	0	-9.57M	40.08M
Gross Margin %	-	-	-	-	-	-	-	-	-8.05%	0.24%
Gross Profit Growth %	0.89%	0.02%	0.03%	-0%	-7.5%	1%	-	-	-	5.19%
Operating Expenses+	27.86M	53.64M	92.88M	128.26M	206.87M	261.94M	342.7M	398.88M	450.99M	435.35M
OpEx % of Revenue	-	-	-	-	-	-	-	-	379.3%	2.65%
Selling, General & Admin	12.39M	17.2M	21.26M	28.43M	40.85M	60.21M	83.66M	104.1M	106.92M	153.02M
SG&A % of Revenue	-	-	-	-	-	-	-	-	89.92%	0.93%
Research & Development	15.47M	28.04M	71.61M	99.83M	166.02M	201.73M	259.04M	294.78M	344.08M	282.34M
R&D % of Revenue	-	-	-	-	-	-	-	-	289.38%	1.72%
Other Operating Expenses	0	9.5M	0	0	0	0	0	0	0	0
Operating Income+	-27.86M	-53.64M	-92.88M	-128.26M	-206.87M	-261.94M	-342.7M	-398.88M	-460.56M	-395.28M
Operating Margin %	-	-	-	-	-	-	-	-	-387.35%	-2.41%
Operating Income Growth %	-1.31%	-0.93%	-0.73%	-0.38%	-0.61%	-0.27%	-0.31%	-0.16%	-0.15%	0.14%
EBITDA+	-26.86M	-52.66M	-91.92M	-127.3M	-198.75M	-260.8M	-328.72M	-377.74M	-427.43M	-351.67M
EBITDA Margin %	-	-	-	-	-	-	-	-	-359.49%	-2.14%
EBITDA Growth %	-1.25%	-0.96%	-0.75%	-0.38%	-0.56%	-0.31%	-0.26%	-0.15%	-0.13%	0.18%
D&A (Non-Cash Add-back)	999K	978K	952K	956K	8.12M	1.14M	13.98M	21.14M	33.13M	43.61M
EBIT	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-261.94M	-342.7M	-398.88M	-460.56M	-395.28M
Net Interest Income+	0	0	0	0	9.32M	2.36M	451K	0	13.04M	20.27M
Interest Income	200K	745K	813K	0	9.32M	2.36M	451K	2.98M	13.04M	20.27M
Interest Expense	200K	0	0	0	0	0	0	2.98M	0	0
Other Income/Expense	200K	745K	813K	4.68M	9.32M	2.36M	451K	2.98M	13.04M	20.27M
Pretax Income+	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-259.58M	-342.25M	-395.89M	-447.52M	-375M
Pretax Margin %	-	-	-	-	-	-	-	-	-376.38%	-2.29%
Income Tax+	0	0	0	0	0	0	0	0	-3.48M	-2.83M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.99%	0.99%
Net Income+	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-259.58M	-342.25M	-395.89M	-444.04M	-372.18M
Net Margin %	-	-	-	-	-	-	-	-	-373.45%	-2.27%
Net Income Growth %	-1.3%	-0.91%	-0.74%	-0.34%	-0.6%	-0.31%	-0.32%	-0.16%	-0.12%	0.16%
Net Income (Continuing)	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-259.58M	-342.25M	-395.89M	-444.04M	-372.18M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.62	-0.96	-1.41	-1.27	-1.50	-1.88	-2.23	-2.49	-1.89	-1.28
EPS Growth %	-0.29%	-0.55%	-0.47%	0.1%	-0.18%	-0.25%	-0.19%	-0.12%	0.24%	0.32%
EPS (Basic)	-0.62	-0.96	-1.41	-1.27	-1.50	-1.88	-2.23	-2.49	-1.89	-1.28
Diluted Shares Outstanding	44.41M	55.27M	65.24M	97.28M	124.34M	138.3M	153.41M	159.26M	235.13M	289.88M
Basic Shares Outstanding	44.41M	55.27M	65.24M	97.28M	124.34M	138.3M	153.41M	159.26M	235.13M	289.88M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	103.98M	169.51M	149.29M	475.37M	316.49M	636.1M	507.96M	479.12M	307.85M	457.02M
Cash & Short-Term Investments	103.7M	166.47M	145.37M	468.52M	307.08M	629.44M	504.41M	471.85M	279.87M	323.78M
Cash Only	103.7M	166.47M	145.37M	82.15M	13.97M	67.33M	78.23M	231.73M	114.89M	115.69M
Short-Term Investments	0	0	0	386.37M	293.11M	562.11M	426.18M	240.11M	164.98M	208.09M
Accounts Receivable	0	0	0	0	0	0	0	0	151K	69.34M
Days Sales Outstanding	-	-	-	-	-	-	-	-	46.35	154.26
Inventory	0	0	0	0	0	0	0	0	10.37M	51.52M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	352	151.66
Other Current Assets	0	3.04M	3.92M	6.85M	0	0	0	7.27M	17.46M	12.38M
Total Non-Current Assets+	1.68M	2.37M	6.08M	5.45M	28.16M	132.36M	269.38M	184.87M	472.5M	453.41M
Property, Plant & Equipment	1.68M	2.37M	2.45M	2.68M	19.23M	113.92M	169.92M	178.25M	176.54M	164.28M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	0.01x	1.00x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	229.26M	282.4M
Long-Term Investments	0	0	0	0	0	0	91.59M	0	66.43M	0
Other Non-Current Assets	0	0	3.63M	2.76M	8.93M	18.44M	7.87M	6.62M	270K	6.73M
Total Assets+	105.65M	171.89M	155.37M	480.82M	344.65M	768.46M	777.33M	663.98M	780.35M	910.43M
Asset Turnover	-	-	-	-	-	-	-	-	0.00x	0.18x
Asset Growth %	1.27%	0.63%	-0.1%	2.09%	-0.28%	1.23%	0.01%	-0.15%	0.18%	0.17%
Total Current Liabilities+	1.63M	4.97M	9.89M	14.4M	39.08M	54.87M	89.2M	91.48M	110.31M	122.34M
Accounts Payable	958K	863K	1.23M	2.74M	15.57M	13.51M	27.38M	26.6M	33.12M	27.51M
Days Payables Outstanding	350.02	322.08	472.35	1.05K	699.49	-	-	-	1.12K	80.98
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	24K	2.52M	5.75M	7.55M	0	0	0	0	34.59M	50.03M
Current Ratio	63.79x	34.12x	15.09x	33.02x	8.10x	11.59x	5.69x	5.24x	2.79x	3.74x
Quick Ratio	63.79x	34.12x	15.09x	33.02x	8.10x	11.59x	5.69x	5.24x	2.70x	3.31x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-725.76	224.94
Total Non-Current Liabilities+	0	0	297K	230K	6.6M	57.09M	66.47M	72.86M	85.43M	77.68M
Long-Term Debt	0	0	0	0	0	0	1M	1M	1M	1M
Capital Lease Obligations	0	0	0	0	4.25M	45.38M	65.47M	71.86M	67.08M	44.37M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	17.35M	32.31M
Other Non-Current Liabilities	0	0	297K	230K	2.35M	11.71M	0	0	0	0
Total Liabilities	1.63M	4.97M	9.89M	14.63M	45.68M	111.96M	155.67M	164.34M	195.74M	200.02M
Total Debt+	0	0	0	0	11.5M	51.66M	71.53M	85.45M	75.86M	58.26M
Net Debt	-103.7M	-166.47M	-145.37M	-82.15M	-2.47M	-15.67M	-6.7M	-146.28M	-39.03M	-57.43M
Debt / Equity	-	-	-	-	0.04x	0.08x	0.12x	0.17x	0.13x	0.08x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-139.30x	-	-	-	-	-	-	-133.63x	-	-
Total Equity+	104.02M	166.92M	145.48M	466.19M	298.97M	656.5M	621.66M	499.64M	584.61M	710.4M
Equity Growth %	1.32%	0.6%	-0.13%	2.2%	-0.36%	1.2%	-0.05%	-0.2%	0.17%	0.22%
Book Value per Share	2.34	3.02	2.23	4.79	2.40	4.75	4.05	3.14	2.49	2.45
Total Shareholders' Equity	104.02M	166.92M	145.48M	466.19M	298.97M	656.5M	621.66M	499.64M	584.61M	710.4M
Common Stock	2K	3K	3K	5K	5K	6K	7K	8K	11K	13K
Retained Earnings	-104.22M	-157.12M	-249.18M	-372.76M	-570.61M	-830.19M	-1.17B	-1.57B	-2.01B	-2.38B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	48K	29K	0	-42K	220K	19K	-601K	-902K	2.53M	-1.05M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.38M	-32.67M	-78.71M	-101.25M	-158.89M	-205.13M	-227.94M	-292.76M	-361.82M	-352.98M
Operating CF Margin %	-	-	-	-	-	-	-	-	-304.31%	-2.15%
Operating CF Growth %	-1.13%	-0.78%	-1.41%	-0.29%	-0.57%	-0.29%	-0.11%	-0.28%	-0.24%	0.02%
Net Income	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-259.58M	-342.25M	-395.89M	-444.04M	-372.18M
Depreciation & Amortization	999K	978K	952K	956K	8.12M	1.14M	13.98M	21.14M	33.13M	43.61M
Stock-Based Compensation	8.52M	18.9M	11.97M	20.03M	24.28M	40.89M	69.77M	84.02M	62.63M	109.63M
Deferred Taxes	0	0	0	0	0	1.86M	0	0	-3.48M	-2.83M
Other Non-Cash Items	8.52M	-74K	19K	-1.32M	8.97M	7.57M	6.01M	871K	-3.54M	-8.65M
Working Capital Changes	-243K	418K	416K	2.67M	-2.7M	2.98M	24.55M	-2.89M	-6.52M	-122.56M
Change in Receivables	0	0	0	0	0	0	0	0	-149K	-69.19M
Change in Inventory	0	0	0	0	0	0	0	0	-10.12M	-39.92M
Change in Payables	-32K	-250K	369K	1.51M	0	-2.96M	6.98M	5.88M	4.83M	-7.84M
Cash from Investing+	-91.15M	8.89M	58.68M	-386.28M	90.03M	-317.85M	132K	256.45M	-155.24M	-96.41M
Capital Expenditures	-1.14M	-1.52M	-1.03M	-1.2M	-6.92M	-46.79M	-37.57M	-20.43M	-22.29M	-11.07M
CapEx % of Revenue	-	-	-	-	-	-	-	-	18.75%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-19.95M	10.41M	59.7M	-385.08M	96.94M	-271.06M	37.71M	276.88M	0	0
Cash from Financing+	78.27M	96.9M	58.69M	424.31M	6.13M	576.42M	239.27M	190.15M	462.96M	390.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-49.45M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-58.35M	50.67M	5.03M	-373.33M	6.44M	9.38M	35.11M	648K	-322K	-6.64M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.52M	-34.19M	-79.74M	-102.45M	-165.81M	-251.93M	-265.51M	-313.18M	-384.11M	-364.05M
FCF Margin %	-	-	-	-	-	-	-	-	-323.05%	-2.22%
FCF Growth %	-0.91%	-0.75%	-1.33%	-0.28%	-0.62%	-0.52%	-0.05%	-0.18%	-0.23%	0.05%
FCF per Share	-0.44	-0.62	-1.22	-1.05	-1.33	-1.82	-1.73	-1.97	-1.63	-1.26
FCF Conversion (FCF/Net Income)	0.66x	0.62x	0.85x	0.82x	0.80x	0.79x	0.67x	0.74x	0.81x	0.95x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-37.16%	-39.04%	-58.94%	-40.41%	-51.64%	-54.34%	-53.55%	-70.61%	-81.91%	-57.48%
Return on Invested Capital (ROIC)	-16138.87%	-10435.6%	-25056.74%	-50.08%	-45.6%	-41.92%	-40.93%	-61.79%	-76.85%	-49.47%
Gross Margin	-	-	-	-	-	-	-	-	-804.54%	24.43%
Net Margin	-	-	-	-	-	-	-	-	-37345.42%	-226.84%
Debt / Equity	-	-	-	-	0.04x	0.08x	0.12x	0.17x	0.13x	0.08x
Interest Coverage	-139.30x	-	-	-	-	-	-	-133.63x	-	-
FCF Conversion	0.66x	0.62x	0.85x	0.82x	0.80x	0.79x	0.67x	0.74x	0.81x	0.95x
Revenue Growth	-	-	-	-	-	-	-	-	-	13698.99%

Revenue by Geography

	2023	2024
UNITED STATES	-	161.04M
UNITED STATES Growth	-	-
Non-US	1.2M	3.03M
Non-US Growth	-	152.25%

Frequently Asked Questions

Growth & Financials

Iovance Biotherapeutics, Inc. (IOVA) reported $250.4M in revenue for fiscal year 2024.

Iovance Biotherapeutics, Inc. (IOVA) grew revenue by 13699.0% over the past year. This is strong growth.

Iovance Biotherapeutics, Inc. (IOVA) reported a net loss of $397.6M for fiscal year 2024.

Dividend & Returns

Iovance Biotherapeutics, Inc. (IOVA) has a return on equity (ROE) of -57.5%. Negative ROE indicates the company is unprofitable.

Iovance Biotherapeutics, Inc. (IOVA) had negative free cash flow of $351.8M in fiscal year 2024, likely due to heavy capital investments.